VLST's business model focuses on utilizing its proprietary platform, combining novel bioinformatics and cutting-edge proteomics, to identify targets for the development of novel biologic therapies that have a far greater likelihood of success in clinical trials than standard discovery methods.

With a wealth of high potential targets, VLST is constantly balancing the need for advancement of our preclinical programs into the clinic with the continued development of our growing list of targets. Our alliance strategy is focused on target- and indication-exclusive partnerships that develop VLST product candidates for commercialization, particularly for autoimmune and inflammatory disorders. Strategic alliances can further be structured on the basis of collaboration roles, territory, and financial risk sharing.

Current Out-Licensing Opportunities

Lead Program: VLST is currently in discussions with leading biotech and pharmaceutical companies regarding possible alliances with its lead product candidate, VLST 007. VLST 007 is in late preclinical development and an IND is scheduled to be filed in the first quarter of 2009. Potential indications for VLST 007 include rheumatoid arthritis, lupus nephritis, mixed cryoglobulinemia, and Wegener's granulomatosis.

Preclinical/Discovery Stage: VLST is actively evaluating key alliances in the US, Europe, and Japan for its discovery and preclinical programs.

Inquiries
For additional information regarding VLST's partnering opportunites, please contact:

Ron Myers
VP Legal Affairs & Intellectual Property
bd@vlstcorp.com